Oliver Mobasser is an associate in the London office of Latham & Watkins. He advises clients in the healthcare and life sciences industry on a range of technology, intellectual property, and data-focused transactions and matters.

Mr Mobasser helps emerging and established multinational pharmaceutical, biotechnology, digital health, and medical technology companies as well as their investors navigate: 

  • Strategic licenses and collaborations
  • Product acquisitions, divestments, and carve-outs
  • Manufacturing, supply, distribution, and other commercial agreements
  • Data protection, as well as data use, re-use, and exploitation
  • Research and development and clinical trials

Prior to joining Latham, Mr. Mobasser practised at a leading law firm in Dublin, Ireland, and completed a secondment as in-house counsel for Shire Pharmaceuticals. He brings a multifaceted, multijurisdictional perspective to his work for clients across Europe and North America. He regularly writes about topics at the intersection of healthcare, technology, and regulation.

* On secondment to the New York office of Latham & Watkins LLP.  Admitted to practice in England & Wales only.

Mr Mobasser’s representative experience includes advising:

  • GSK on:
    • A strategic global collaboration and licensing agreement with Alector for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies for a range of neurodegenerative diseases
    • A global license and collaboration with SpringWorks Therapeutics for development and commercialization of SpringWorks’ nirogacestat product and GSK’s Blenrep product 
    • Several early-stage clinical trial, collaboration, development, and supply arrangements
    • The divestment of its Prevacid 24HR business to Perrigo Company
    • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia
    • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group
    • The divestment of four established over-the-counter brands in eight countries to Pharma SGP
  • Swedish Orphan Biovitrum AB (publ) (Sobi™) on matters including:
    • A strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million
    • A strategic licensing and collaboration agreement with Apellis Pharmaceuticals for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan
    • Streamlining and simplifying the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of its participation agreement with AstraZeneca 
    • Its US$1.7 billion acquisition of CTI BioPharma Corp, a biopharmaceutical company focused on blood-related cancers and rare diseases 
  • Norgine, a Netherlands-based specialty pharmaceutical company, in its US$2 billion sale to Goldman Sachs
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialise and launch Linzagolix, an oral GnRH antagonist
  • Astorg and OPEN Health on data protection matters related to the acquisition of The CM Group, an integrated commercialization platform
  • Lindsay Goldberg, on data protection matters related to its investment in MMS Holdings, a leading data-focused contract research organization
  • A consortium of Astorg Asset Management, Nordic Capital, Novo Holdings — and their portfolio company eResearchTechnologies, on the data privacy aspects of its merger with Bioclinica, a technological and scientific leader in clinical imaging
  • Frontier Medicines on the data privacy aspects of its global partnership with AbbVie to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
  • BC Partners on IP, contracts, data protection and regulatory matters related to the acquisition of a majority interest in Synthon International Holding B.V., Various pharmaceutical and medical technology companies on agreements for the conduct of clinical trials in the EU, including GDPR compliance aspects
  • Leadiant Biosciences on the sale of its assets relating to Revcovi, a pharmaceutical product for the treatment of a rare immunodeficiency disease, to Chiesi Farmaceutici
  • Novo Holdings A/S on its acquisition of BBI Group, a leading supplier of products and services, to the global diagnostics and life sciences industries
  • Acino Pharma in relation to its purchase of a portfolio of over-the-counter and prescription pharmaceutical products in the Near East, Middle East, and Africa for a total value in excess of US$200 million
  • Oasmia Pharmaceutical AB on its global strategic partnership for the development and commercialization of its proprietary anticancer product, Apealea, with Elevar Therapeutics, with a deal value of approximately US$698 million
  • Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
  • Permira, on contracts, regulatory, and IP matters related to the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory, two leading providers of medicinal products derived from human blood plasma
  • Permira on data protection, contracts, regulatory, and IP matters related to the acquisition of Quotient Sciences, a provider of contract development and manufacturing and contract research services to pharma and biotech companies
  • Quotient Sciences on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization

Bar Qualification

  • England and Wales (Solicitor)


  • BCL in Law & Philosophy, University College Dublin, 2012
    First Class